Aktuellt
SENASTE
Redeye notes that the first hospital in the US trial with Emcitate (ReTRIACt) has been activated and that the study duration and timeline for submission, now mid-24, have been extended (to our understanding due to hospital capacity and number of treatment naïve patients). Following this update, the company will focus its efforts on Emcitate and in-house development of Aladote will be paused until submissions are finalized. We will review our estimates and return after the call at 3pm.
LÄS MER
